Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elemene Liposomes Combined With TC Chemotherapy in Advanced or Recurrent Endometrial Cancer
NCT07738315Phase 2Not yet recruiting
- Sponsor
- Women's Hospital, Zhejiang University School of Medicine
- Start
- Aug 2026
- Primary completion
- Aug 2031
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Elemene in endometrial carcinoma (2 arms), sponsored by Women's Hospital, Zhejiang University School of Medicine. Primary endpoint: Progression-Free Survival Rate at 24 months. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
Elemene
03
Conditions
endometrial carcinoma
Beyond the preview
Go deeper on NCT07738315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07738315.